Trial Profile
Phase I/II study of temozolomide and Gleevec (imatinib mesylate [imatinib], formerly known as STI571) in advanced melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2020 Status changed from completed to discontinued.
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 Status changed from completed to active, no longer recruiting.